MCID: PLC008
MIFTS: 51

Placenta Disease

Categories: Fetal diseases, Rare diseases

Aliases & Classifications for Placenta Disease

MalaCards integrated aliases for Placenta Disease:

Name: Placenta Disease 12 15 17
Pregnancy Complications 44 72
Placenta Disorder 75 53
Placenta Diseases 53 44
Placenta Disorders 72

Classifications:



External Ids:

Disease Ontology 12 DOID:780
ICD9CM 35 646.9
SNOMED-CT 68 23288008 90821003
ICD10 33 O43 O43.9 O43.90
UMLS 72 C0032045 C0032962 C0151864 more

Summaries for Placenta Disease

Disease Ontology : 12 A uterine disease that is located in the placenta.

MalaCards based summary : Placenta Disease, also known as pregnancy complications, is related to antiphospholipid syndrome and placental insufficiency, and has symptoms including hyperemesis gravidarum, morning sickness and late pregnancy bleeding. An important gene associated with Placenta Disease is MTHFR (Methylenetetrahydrofolate Reductase), and among its related pathways/superpathways is Glucocorticoid receptor regulatory network. The drugs Remifentanil and Silicon have been mentioned in the context of this disorder. Affiliated tissues include placenta, testes and ovary, and related phenotype is homeostasis/metabolism.

Wikipedia : 75 A placental disease is any disease, disorder, or pathology of the... more...

Related Diseases for Placenta Disease

Diseases related to Placenta Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 823)
# Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 32.6 SERPINC1 MTHFR F5 F3 APOH ANXA5
2 placental insufficiency 32.5 PGF F3 AFP
3 oligohydramnios 32.3 OXT CGA AFP
4 placental abruption 32.2 SERPINC1 PGF MTHFR F5 APOH
5 severe pre-eclampsia 31.5 SERPINC1 PGF F5 APOH
6 eclampsia 31.3 SERPINC1 PGF PAPPA OXT MTHFR
7 thrombophilia 31.1 SERPINC1 MTHFR F5 F3 APOH
8 disseminated intravascular coagulation 31.0 SERPINC1 F5 F3
9 chromosomal triplication 30.9 CGB3 CGA AFP
10 purpura 30.9 SERPINC1 IL6 F3 APOH
11 teratoma 30.8 CGB3 CGA AFP
12 gastroschisis 30.8 MTHFR IL6 F5
13 endocarditis 30.8 SERPINC1 IL6 APOH
14 homocysteinemia 30.7 SERPINC1 MTHFR F5
15 cerebral palsy 30.6 MTHFR IL6 F5
16 ectopic pregnancy 30.6 PGF PAPPA CGB7 CGB3 CGA
17 pulmonary embolism 30.6 SERPINC1 MTHFR F5 F3 APOH
18 thrombophilia due to thrombin defect 30.5 SERPINC1 MTHFR F5 F3 APOH
19 endometritis 30.4 PGF OXT IL6
20 thrombophlebitis 30.4 SERPINC1 MTHFR F5 APOH
21 thrombosis 30.3 SERPINC1 MTHFR F5 F3 APOH
22 varicose veins 30.3 SERPINC1 MTHFR F5
23 vascular disease 30.3 SERPINC1 MTHFR IL6 F5 F3 APOH
24 thrombophilia due to activated protein c resistance 30.3 SERPINC1 MTHFR F5 F3 APOH
25 rh isoimmunization 30.2 OXT CSH2 CSH1 AFP
26 sacrococcygeal teratoma 30.2 CGB7 CGA AFP
27 pre-eclampsia 30.2 SERPINC1 PGF PAPPA OXT MTHFR IL6
28 protein s deficiency 30.2 SERPINC1 MTHFR F5 F3 APOH
29 prothrombin deficiency, congenital 30.2 SERPINC1 F5 APOH
30 protein c deficiency 30.2 SERPINC1 MTHFR F5
31 arteries, anomalies of 30.2 SERPINC1 PGF IL6 F3
32 pregnancy loss, recurrent 1 30.1 F5 APOH
33 hellp syndrome 30.1 SERPINC1 PGF MTHFR IL6 HADHA F5
34 down syndrome 30.1 PAPPA MTHFR CGB7 CGB3 AFP
35 triploidy 30.1 PAPPA CGB7 CGA AFP
36 gestational trophoblastic neoplasm 30.0 OXT LGALS1 CSH2 CSH1
37 portal vein thrombosis 30.0 SERPINC1 MTHFR F5 APOH AFP
38 orofaciodigital syndrome viii 30.0 PAPPA CGA AFP
39 antithrombin iii deficiency 30.0 SERPINC1 MTHFR F5 APOH
40 catastrophic antiphospholipid syndrome 30.0 MTHFR F5 F3 APOH
41 thrombocytosis 29.9 SERPINC1 IL6 F3
42 cerebrovascular disease 29.8 MTHFR IL6 F5
43 choriocarcinoma 29.8 CSH2 CSH1 CGB7 CGB3 CGA
44 intracranial hypertension 29.7 SERPINC1 MTHFR F5 F3 APOH
45 budd-chiari syndrome 29.7 SERPINC1 MTHFR F5 F3 APOH
46 germ cell cancer 29.7 MIR371A CGA AFP
47 stroke, ischemic 29.7 SERPINC1 MTHFR F5 F3 APOH
48 uterine anomalies 29.5 OXT IL6 CSH2 CSH1 AFP
49 hepatic infarction 29.2 SERPINC1 OXT MTHFR HADHA F3 APOH
50 myocardial infarction 29.2 SERPINC1 PGF PAPPA MTHFR IL6 F5

Graphical network of the top 20 diseases related to Placenta Disease:



Diseases related to Placenta Disease

Symptoms & Phenotypes for Placenta Disease

UMLS symptoms related to Placenta Disease:


hyperemesis gravidarum, morning sickness, late pregnancy bleeding, maternal fever, intrapartum fever

MGI Mouse Phenotypes related to Placenta Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.44 AFP APOH CGA F3 F5 HADHA

Drugs & Therapeutics for Placenta Disease

Drugs for Placenta Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Remifentanil Approved Phase 4 132875-61-7 60815
2
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
6
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432 71715
7
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
8
Clarithromycin Approved Phase 4 81103-11-9 84029
9
Tranexamic Acid Approved Phase 4 1197-18-8 5526
10
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
11
Enoxaparin Approved Phase 4 9005-49-6 772
12
Dalteparin Approved Phase 4 9005-49-6
13
Metronidazole Approved Phase 4 443-48-1 4173
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Fibrinolysin Investigational Phase 4 9004-09-5
18 Hypoglycemic Agents Phase 4
19 Acidophilus Phase 4
20 Narcotics Phase 4
21 Analgesics, Opioid Phase 4
22 Anesthetics, Intravenous Phase 4
23 Sulfalene Phase 4
24 Bifidobacterium Phase 4
25 Nucleic Acid Synthesis Inhibitors Phase 4
26 alanine Phase 4
27 Ferric Compounds Phase 4
28 Ferric Oxide, Saccharated Phase 4
29 Coagulants Phase 4
30 Antifibrinolytic Agents Phase 4
31 Hemostatics Phase 4
32 Neurotransmitter Agents Phase 4
33 Pharmaceutical Solutions Phase 4
34 Contraceptive Agents Phase 4
35 Hormones Phase 4
36 Luteolytic Agents Phase 4
37 Hormone Antagonists Phase 4
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
39 Calcium, Dietary Phase 4
40 calcium heparin Phase 4
41 Chorionic Gonadotropin Phase 4
42 Anticoagulants Phase 4
43 Fibrinolytic Agents Phase 4
44 Heparin, Low-Molecular-Weight Phase 4
45 Triptorelin Pamoate Phase 4
46 Follicle Stimulating Hormone Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 Anti-Bacterial Agents Phase 4
49 Antibiotics, Antitubercular Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 386)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
2 The POP-study: Effect of Probiotics on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn - a Randomized, Double-blind Placebo Controlled Trial With Vivomixx® Unknown status NCT02508844 Phase 4
3 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
4 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
5 Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW Completed NCT00190294 Phase 4 MIFEPRISTONE 200 mg and misoprostol 400 µg
6 Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels Completed NCT01337791 Phase 4 Telbivudine treatment
7 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
8 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
9 Vitamin D Dose-response Study Throughout Pregnancy and Lactation Completed NCT01112891 Phase 4 Vitamin D;Vitamin D3;Vitamin D
10 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
11 The Clinical Carbetocin Myocardium Trial Part 2 Recruiting NCT03899961 Phase 4 Oxytocin;Carbetocin
12 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Recruiting NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
13 Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk Recruiting NCT02797119 Phase 4 tranexamic acid 1 g (TA1);tranexamic acid 0.5 g (TA1/2);Saline Solution (TA0)
14 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
15 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Enrolling by invitation NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
16 Effect of Low-Molecular-Weight-Heparin (LMWH) on Pregnancy Outcome in Women With Multiple Failures of IVF-ET Not yet recruiting NCT03701750 Phase 4 Low Molecular Weight Heparin (enoxaparin sodium)
17 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
18 Prolonged Treatment for Infected Abortion After Hospital Discharge. Terminated NCT00376493 Phase 4 metronidazole and doxycycline
19 Vitamin D During In Vitro Fertilisation (IVF) - A Prospective Randomized Trial Unknown status NCT01019785 Phase 3
20 Low Molecular Weight Heparin for Pregnant Women With Thrombophilia: a Prospective, Randomized, Open Trial Unknown status NCT01019655 Phase 3 Nadroparin calcium
21 Does Routine Membrane Sweeping in Uncomplicated Term Pregnancies Increase the Rate of Prelabour Rupture of Membranes Unknown status NCT00294242 Phase 3
22 Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial Unknown status NCT01635426 Phase 2, Phase 3 Aspirin;Clopidogrel
23 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial Unknown status NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
24 Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus: A Randomized Controlled Trial Unknown status NCT02838147 Phase 3
25 Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial Completed NCT01388322 Phase 3 Enoxaparin
26 Randomised Placebo-controlled Study of Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy Completed NCT01576458 Phase 3 ursodeoxycholic acid;Placebo
27 A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy Completed NCT00614445 Phase 3 doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg;Placebo
28 Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT) Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
29 Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection Completed NCT00197561 Phase 3
30 TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women. Completed NCT00967382 Phase 3 dalteparin sodium
31 Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation Completed NCT01735669 Phase 3 Remifentanil;Nitrous Oxide
32 Impact of Periodontal Therapy on Endothelial Function Completed NCT00681564 Phase 3
33 Trial of Vitamins Among Children of HIV-infected Women Completed NCT00197730 Phase 3 Multivitamins - vitamins B complex, C and E;Placebo
34 A Randomized, Open-Label, Study of Pre-emptive Diclectin® Treatment for Severe Nausea and Vomiting of Pregnancy Completed NCT00293644 Phase 3 Diclectin®
35 A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates Completed NCT00006396 Phase 3 Nevirapine;Zidovudine
36 A Phase III Randomized Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerance of Oral Zidovudine (AZT) in Pregnant HIV Infected Women and Their Infants Completed NCT00000960 Phase 3 Zidovudine
37 A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) Completed NCT00000751 Phase 3 Anti-HIV Immune Serum Globulin (Human);Globulin, Immune;Zidovudine
38 Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women? Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
39 Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy Completed NCT00017719 Phase 3 Lamivudine;Lamivudine/Zidovudine;Nelfinavir mesylate;Nevirapine;Zidovudine
40 A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00001135 Phase 3 Nevirapine
41 Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin Completed NCT00131235 Phase 3 Sulfadoxine-pyrimethamine treatment twice during pregnancy;Sulfadoxine-pyrimethamine at 4-week intervals;Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
42 A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00000942 Phase 3 Nevirapine
43 A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women Completed NCT00000869 Phase 3 Nevirapine
44 Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation Completed NCT01932788 Phase 3 Vitamin D3 4000 IU in gummy form;Placebo gummy vitamin
45 Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy Recruiting NCT02932475 Phase 3 Metformin;Placebo
46 Feasibility Study of the Measurement of the Placental Perfusion During the First Trimester of Pregnancy by 3D Doppler Echo-angiography With a Contrast Agent Recruiting NCT02884297 Phase 3 Contrast agent: SonoVue®.
47 Impact of Home-based Oxygen Therapy on Maternal and Fetal Complications, in Pregnant Women With Sickle Cell Disease. A Randomized Multi-center Trial. Recruiting NCT02813850 Phase 3
48 Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D Active, not recruiting NCT02434380 Phase 3
49 A Randomised Controlled Trial Comparing the Effect of the Faster-acting Insulin Analog - Insulin Fiasp® - Versus Insulin Novorapid® in the Treatment of Women With Type 1 or Type 2 Diabetes During Pregnancy and Lactation Not yet recruiting NCT03770767 Phase 3 Faster-acting Aspart insulin Fiasp;Control (insulin Novorapid)
50 METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study Not yet recruiting NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid

Search NIH Clinical Center for Placenta Disease

Cochrane evidence based reviews: placenta diseases

Genetic Tests for Placenta Disease

Anatomical Context for Placenta Disease

MalaCards organs/tissues related to Placenta Disease:

41
Placenta, Testes, Ovary, Heart, Endothelial, Thyroid, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Placenta Disease:

19
Placenta

Publications for Placenta Disease

Articles related to Placenta Disease:

(show top 50) (show all 5066)
# Title Authors PMID Year
1
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 9 38
20363656 2010
2
Full-length adiponectin attenuates insulin signaling and inhibits insulin-stimulated amino Acid transport in human primary trophoblast cells. 9 38
20150288 2010
3
Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions. 9 38
20132984 2010
4
The relationship between unexplained elevated serum markers in triple test, uterine artery Doppler measurements and adverse pregnancy outcome. 9 38
20225773 2010
5
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. 9 38
19556010 2009
6
[Thrombophilia, preeclampsia and other pregnancy complications]. 9 38
20034330 2009
7
Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. 9 38
19232551 2009
8
[Angiogenic factors and their role in pathogenesis and prediction of preeclampsia]. 9 38
19536710 2009
9
Does thrombophilia testing help in the clinical management of patients? 9 38
18710381 2008
10
Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. 9 38
18827058 2008
11
Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. 9 38
18814068 2008
12
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. 9 38
18175241 2008
13
The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. 9 38
18028481 2008
14
Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. 9 38
17720945 2007
15
Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. 9 38
17468256 2007
16
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. 9 38
17302880 2007
17
Acute liver failure in pregnancy associated with maternal MCAD deficiency. 9 38
17186412 2007
18
[Genomic diagnosis of thrombophilia in women: clinical relevance]. 9 38
17279273 2007
19
Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. 9 38
17919116 2007
20
Determination of hyperglycosylated human chorionic gonadotropin produced by malignant gestational trophoblastic neoplasias and male germ cell tumors using a lectin-based immunoassay and surface plasmon resonance. 9 38
17081681 2007
21
Factor V Leiden, pregnancy complications and adverse outcomes. 9 38
16931620 2006
22
Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. 9 38
16855163 2006
23
[Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]. 9 38
17195354 2006
24
Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. 9 38
16613994 2006
25
Evaluation of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase gene mutations in patients with severe pregnancy complications in northern Finland. 9 38
16514238 2006
26
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. 9 38
16086443 2005
27
Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome? 9 38
15858960 2005
28
[Impact of inherited thrombophilia on the development of some pregnancy complications]. 9 38
16313049 2005
29
Elevated second-trimester free beta-hCG as an isolated finding and pregnancy outcomes. 9 38
15539871 2004
30
Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. 9 38
15210385 2004
31
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome? 9 38
15099868 2004
32
Maternal serum free beta-hCG levels in uncomplicated pregnancies at the 10th-15th week of gestation and the development of obstetric complications. 9 38
15018435 2004
33
Haemostatic changes in pregnancy. 9 38
15507271 2004
34
Pronto ThromboRisk--a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia. 9 38
15356875 2004
35
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. 9 38
14663836 2003
36
Maternal midtrimester free beta-HCG and AFP serum levels in spontaneous singleton pregnancies complicated by gestational diabetes mellitus, pregnancy-induced hypertension or obstetric cholestasis. 9 38
14691989 2003
37
Human chorionic gonadotropin and vascular endothelial growth factor in normal and complicated pregnancies. 9 38
14672476 2003
38
Characterization of a pseudogene for murine methylenetetrahydrofolate reductase. 9 38
14577615 2003
39
Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. 9 38
14526312 2003
40
Autoimmune disease as a cause of reproductive failure. 9 38
12848445 2003
41
Procoagulant and anticoagulant mechanisms in human placenta. 9 38
12709921 2003
42
[Factor V Leiden mutation and pregnancy complications]. 9 38
14515043 2003
43
Multiple transcription start sites and alternative splicing in the methylenetetrahydrofolate reductase gene result in two enzyme isoforms. 9 38
12370778 2002
44
[Genetic mutations, acquired coagulation system disorders and obstetric pathology. Personal experience]. 9 38
11828266 2002
45
[Effect of thrombophilic factors on thromboembolism and other pregnancy complications]. 9 38
11570192 2001
46
Postnatal screening for thrombophilia in women with severe pregnancy complications. 9 38
11339929 2001
47
Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. 9 38
11295727 2001
48
Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. 9 38
12083967 2001
49
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. 9 38
11028579 2000
50
The influence of parity and gravidity on first trimester markers of chromosomal abnormality. 9 38
11038455 2000

Variations for Placenta Disease

Expression for Placenta Disease

Search GEO for disease gene expression data for Placenta Disease.

Pathways for Placenta Disease

Pathways related to Placenta Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.71 IL6 CGA AFP

GO Terms for Placenta Disease

Cellular components related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SERPINC1 PGF PAPPA OXT LGALS1 IL6
2 endoplasmic reticulum lumen GO:0005788 9.65 SERPINC1 LGALS1 IL6 F5 AFP
3 collagen-containing extracellular matrix GO:0062023 9.55 SERPINC1 LGALS1 F3 APOH ANXA5
4 extracellular space GO:0005615 9.5 SERPINC1 PGF PAPPA OXT LGALS1 IL6

Biological processes related to Placenta Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.86 PGF MTHFR LGALS1 HADHA
2 platelet degranulation GO:0002576 9.76 F5 APOH ANXA5
3 post-translational protein modification GO:0043687 9.72 SERPINC1 LGALS1 IL6 F5 AFP
4 female pregnancy GO:0007565 9.7 PGF PAPPA OXT
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL6 CSH2 CSH1
6 blood coagulation GO:0007596 9.67 SERPINC1 F5 F3 ANXA5
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL6 CSH2 CSH1
8 peptide hormone processing GO:0016486 9.58 CGB3 CGA
9 response to glucocorticoid GO:0051384 9.58 PAPPA OXT IL6
10 female gamete generation GO:0007292 9.57 CGB7 CGB3
11 animal organ development GO:0048513 9.55 CSH2 CSH1
12 negative regulation of blood coagulation GO:0030195 9.54 APOH ANXA5
13 regulation of blood coagulation GO:0030193 9.51 SERPINC1 APOH
14 positive regulation of growth GO:0045927 9.48 CSH2 CSH1
15 growth hormone receptor signaling pathway GO:0060396 9.46 CSH2 CSH1
16 hemostasis GO:0007599 9.46 SERPINC1 F5 F3 ANXA5
17 positive regulation of JAK-STAT cascade GO:0046427 9.43 IL6 CSH2 CSH1
18 cellular protein metabolic process GO:0044267 9.43 SERPINC1 PAPPA LGALS1 IL6 F5 AFP
19 regulation of signaling receptor activity GO:0010469 8.32 CGA

Molecular functions related to Placenta Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.5 F3 APOH ANXA5
2 growth factor activity GO:0008083 9.46 PGF IL6 CSH2 CSH1
3 growth hormone receptor binding GO:0005131 9.26 CSH2 CSH1
4 heparin binding GO:0008201 9.26 SERPINC1 PGF APOH ANXA5
5 hormone activity GO:0005179 9.1 OXT CSH2 CSH1 CGB7 CGB3 CGA

Sources for Placenta Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....